Analyst Rating: Will Surface Oncology Inc (SURF) Stock Outperform the Market?

Friday, September 17, 2021 10:23 AM | InvestorsObserver Analysts

Mentioned in this article

Analyst Rating: Will Surface Oncology Inc (SURF) Stock Outperform the Market?

Wall Street is positive on Surface Oncology Inc (SURF). On average, analysts give Surface Oncology Inc a Strong Buy rating. The average price target is $15, which means analysts expect the stock to add by 132.92% over the next twelve months. That average ranking earns Surface Oncology Inc an Analyst Rating of 75, which is better than 75% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating SURF a Strong Buy today. Find out what this means to you and get the rest of the rankings on SURF!

See Full SURF Report

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Surface Oncology Inc Stock Today?

Surface Oncology Inc (SURF) stock is higher by 7.12% while the S&P 500 is lower by -0.54% as of 10:22 AM on Friday, Sep 17. SURF has risen $0.43 from the previous closing price of $6.01 on volume of 740,375 shares. Over the past year the S&P 500 has gained 32.54% while SURF is lower by -7.74%. SURF earned $0.11 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 56.08. Click Here to get the full Stock Report for Surface Oncology Inc stock.